Abstract
Anxiety and depression are pathologies that affect human beings in many aspects of life, including social life, productivity and health. Cannabidiol (CBD) is a constituent non-psychotomimetic of Cannabis sativa with great psychiatric potential, including uses as an antidepressant-like and anxiolytic-like compound. The aim of this study is to review studies of animal models using CBD as an anxiolytic-like and antidepressant-like compound. Studies involving animal models, performing a variety of experiments on the above-mentioned disorders, such as the forced swimming test (FST), elevated plus maze (EPM) and Vogel conflict test (VCT), suggest that CBD exhibited an anti-anxiety and antidepressant effects in animal models discussed. Experiments with CBD demonstrated non-activation of neuroreceptors CB1 and CB2. Most of the studies demonstrated a good interaction between CBD and the 5-HT1A neuro-receptor.
Keywords: Anxiety, anxiolytic-like, cannabis sativa, cannabidiol, CBD, major depression.
CNS & Neurological Disorders - Drug Targets
Title:Antidepressant-Like and Anxiolytic-Like Effects of Cannabidiol: A Chemical Compound of Cannabis sativa
Volume: 13 Issue: 6
Author(s): Alexandre R. de Mello Schier, Natalia P. de Oliveira Ribeiro, Danielle S. Coutinho, Sergio Machado, Oscar Arias-Carrion, Jose A. Crippa, Antonio W. Zuardi, Antonio E. Nardi and Adriana C. Silva
Affiliation:
Keywords: Anxiety, anxiolytic-like, cannabis sativa, cannabidiol, CBD, major depression.
Abstract: Anxiety and depression are pathologies that affect human beings in many aspects of life, including social life, productivity and health. Cannabidiol (CBD) is a constituent non-psychotomimetic of Cannabis sativa with great psychiatric potential, including uses as an antidepressant-like and anxiolytic-like compound. The aim of this study is to review studies of animal models using CBD as an anxiolytic-like and antidepressant-like compound. Studies involving animal models, performing a variety of experiments on the above-mentioned disorders, such as the forced swimming test (FST), elevated plus maze (EPM) and Vogel conflict test (VCT), suggest that CBD exhibited an anti-anxiety and antidepressant effects in animal models discussed. Experiments with CBD demonstrated non-activation of neuroreceptors CB1 and CB2. Most of the studies demonstrated a good interaction between CBD and the 5-HT1A neuro-receptor.
Export Options
About this article
Cite this article as:
Schier R. de Mello Alexandre, Ribeiro P. de Oliveira Natalia, Coutinho S. Danielle, Machado Sergio, Arias-Carrion Oscar, Crippa A. Jose, Zuardi W. Antonio, Nardi E. Antonio and Silva C. Adriana, Antidepressant-Like and Anxiolytic-Like Effects of Cannabidiol: A Chemical Compound of Cannabis sativa, CNS & Neurological Disorders - Drug Targets 2014; 13 (6) . https://dx.doi.org/10.2174/1871527313666140612114838
DOI https://dx.doi.org/10.2174/1871527313666140612114838 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Thrombomodulin Links Coagulation to Inflammation and Immunity
Current Drug Targets Prenatal Cocaine Disrupts Serotonin Signaling-Dependent Behaviors:Implications for Sex Differences, Early Stress and Prenatal SSRI Exposure
Current Neuropharmacology Determination of Homocysteine in Human Saliva by Liquid Chromatography and Electrospray Ionization Quadrupole Time-of-flight Mass Spectrometry: Profiles in Healthy Adults
Protein & Peptide Letters Application of Chemoinformatic Tools for the Design of Novel Molecules as anti-Parkinsonian Agents
Current Signal Transduction Therapy Fetzima (levomilnacipran), a Drug for Major Depressive Disorder as a Dual Inhibitor for Human Serotonin Transporters and Beta-Site Amyloid Precursor Protein Cleaving Enzyme-1
CNS & Neurological Disorders - Drug Targets Progress in Multiple Sclerosis Genetics
Current Genomics Analgesia for Children in Acute Pain in the Post-codeine Era
Current Pediatric Reviews Therapeutic Manipulation of the Immune System: Enhancement of Innate and Adaptive Mucosal Immunity
Current Pharmaceutical Design A Review of Rehabilitation Devices to Promote Upper Limb Function Following Stroke
Neuroscience and Biomedical Engineering (Discontinued) IL-6 Activated JAK/STAT3 Pathway and Sensitivity to Hsp90 Inhibitors in Multiple Myeloma
Current Medicinal Chemistry Fragment-based Designing for the Generation of Novel Leads Against BACE1
Central Nervous System Agents in Medicinal Chemistry Vertical and Horizontal Convergences of Targeting Pathways in Combination Therapy with Baicalin and Jasminoidin for Cerebral Ischemia
CNS & Neurological Disorders - Drug Targets Recent Advances in the Synthesis and Applications of Reduced Amide Pseudopeptides
Current Medicinal Chemistry Safety and Efficacy Assessment of a Sanitary Pad Containing Potassium Alum in Comparison to Ordinary Pads: A Cross-Over Trial
Current Women`s Health Reviews Pharmacologic Strategies for Suppression of Lipid Peroxidation in Neurodegeneration
Current Neuropharmacology Targeting the Bombesin/Gastrin-Releasing Peptide Receptor to Treat Sepsis
Recent Patents on Anti-Infective Drug Discovery The Biological Activity of the Novel Vinca Alkaloids 4-chlorochablastine and 4-chlorochacristine
Current Cancer Drug Targets Neuroimaging Correlates of Pharmacological and Psychological Treatments for Specific Phobia
CNS & Neurological Disorders - Drug Targets Interaction Between Platelets and Cytokines - A Possible Role in the Pathogenesis of Preeclampsia
Vascular Disease Prevention (Discontinued) Vortioxetine vs. Other Antidepressants in Patients with Major Depressive Episode With or Without Substance Use Disorder
Current Neuropharmacology